Archive for month: August, 2020

In Its 41^st year, the Arab Health Congress, organized by Informa Life Sciences Exhibitions, will provide a new perspective in the field of 3D printing and how it will revolutionize healthcare. The conference will focus on the surgical applications for 3D printing, 3D printing for drug discovery, bioprinting and vascularization, as well as a look at the legal and ethical debates surrounding this technology.
3D bioprinting has enormous potential to save lives. Companies who are able to 3D print liver tissue for instance are scarce at the moment. The next step in the field of 3D bioprinting is being able to print complete organs such as the pancreas, kidney, liver and vascular networks. This procedure could significantly increase the chances of organ survival.

Penn Medicine has performed more than 1,200 Transcatheter Aortic Valve Replacements (TAVR) on patients with severe aortic stenosis. At the Transcatheter Cardiac Therapeutics conference in San Francisco, Howard C. Herrmann, MD, the John Winthrop Bryfogle Professor of Cardiovascular Diseasesand director of Penn Medicine

A trial that uses stem cell injections to treat osteogenesis imperfecta, more commonly known as brittle bone disease, prior to and just after birth has been launched by teams at Great Ormond Street Hospital (GOSH) and the UCL Institute of Child Health (ICH) in collaboration with colleagues across Europe.

By carrying out genetic screening in pregnant women whose baby is suspected of having severe osteogenesis imperfecta (OI), babies identified with the condition may be treated with a stem cell that increases the production of collagen in the body. This then reduces the number of painful bone fractures a child experiences once born.

OI affects around one in 15

In clinical situations in which there are two or more possible courses of action, patients should be given the opportunity to compare options and to clarify which suits them best, after considering their risks and benefits. Patient involvement in treatment decisions is now one of the ethical fundamentals of physicians

A minimally invasive implant procedure is highly effective in reducing pain and disability for patients with sacroiliac joint (SIJ) dysfunction, reports a clinical trial.

The randomized controlled trial shows superior outcomes in patients undergoing minimally invasive sacroiliac joint (SIJ) fusion using triangular titanium implants, compared to nonsurgical management, according to the new research overseen by Dr. Daniel J. Cher of SI-BONE, Inc., in San Jose, Calif.

The study included 148 patients with low back pain caused by confirmed SIJ dysfunction, treated at 19 US spine surgery clinics. The SIJ connects the central (sacrum) and lateral (ilium) bones of the pelvis. SIJ disruption or osteoarthritis is a common pain condition, estimated to cause 15 to 23 percent of cases of chronic low back pain.

Trial subjects had severe SIJ pain, with an average pain score of 82 on a 0-to-100-point scale. Average pain duration was longer than six years, and about two-thirds of subjects were taking opioid (narcotic) medications. Many had previously received many non-surgical SIJ treatments, and many had a history of prior spinal surgery.

Two-thirds of subjects were randomly assigned to undergo minimally invasive SIJ fusion. In this procedure, triangular titanium implants were placed through a small incision to stabilize and fuse the SIJ. Procedures were unilateral in most cases, but some subjects underwent bilateral treatment. The remaining subjects received nonsurgical treatments, such as physical therapy, steroid injections and/or radiofrequency ablation of sacral nerve root lateral branches.

Pain and other outcomes were compared at baseline and at 1, 3, 6 and 12 months. At 6 months, subjects in the nonsurgical group had the option to ‘cross over’ to the implant procedure.

Based on reduction in pain and absence of complications at 6 months, treatment was rated successful in 81 percent of subjects assigned to the SIJ implant procedure, compared to 26 percent with nonsurgical treatment. Average pain score decreased to 30 in the surgical group versus 72 in the nonsurgical group. Seventy-three percent of subjects undergoing the implant procedure had ‘clinically significant’ reduction in disability scores, compared to just 14 percent in the nonsurgical group.

After one year, subjects assigned to SIJ fusion still had significant reductions in pain and disability, as well as improved quality of life. Thirty-five subjects from the nonsurgical group opted to undergo the implant procedure, with similarly good results. There were only a few complications related to the SIJ implant procedure. EurekAlert